On March 19, 2026, Shanghai Escugen Biotechnology Co., Ltd. successfully passed the National High-Tech Enterprise certification and officially obtained the "High-Tech Enterprise" certificate. This qualification is a high recognition of Escugen Bio's comprehensive strength in innovative drug pipeline layout, ADC technology R&D, independent intellectual property accumulation, and transformation of scientific and technological achievements. It also demonstrates the company's steadfast commitment to independent innovation in the innovative drug field over the years.

Recently, Shanghai Escugen Biotechnology Co., Ltd. (hereinafter referred to as "Escugen") and Shanghai GFK Pharmaceutical Engineering Technology Co., Ltd. (hereinafter referred to as "GFK") officially signed a cooperation agreement. Under the agreement, GFK will leverage its independently developed AI Bio-Big Data Intelligent Platform to provide Escugen with accurate and efficient target discovery services, helping Escugen expand the boundaries of innovative R&D. In turn, Escugen will give full play to its strengths in innovative drug R&D to accelerate the new drug development process.